Hesai Gr (NASDAQ:HSAI) 株価情報

Hesai Gr

Hesai Group is engaged in the development, manufacture, and sales of three-dimensional light detection and ranging solutions, or LiDAR. Its LiDAR products enable a broad spectrum of applications across passenger or commercial vehicles with advanced driver assistance systems, or ADAS, autonomous vehicle fleets providing passenger and freight mobility services, or Autonomous Mobility, and other applications such as last-mile delivery robots, street sweeping robots, and logistics robots in restricted areas, or Robotics. Geographically, the company operates in North America, Mainland China, Europe, and Other regions.

benzingaai2023_modern_computer_screen_with_stock_chart_stock__c8dae12f-563b-4c3d-ba96-79a17f4c62e4_0

News

Movers

HSAI

ブルー・オルカ・キャピタルの報告書の発表後、ホーサイ（NASDAQ:HSAI）の株式が下落した。

火曜日、ホーサイの株価がほぼ8%下落した理由

Asia

Penny Stocks

Small Cap

Markets

General

BIDU

要点WeRideが、売上高の減少と損失の拡大を報告しつつ、100億ドル以上の時価総額を誇るという自己紹介のもと、米国に上場を申請した同社のR&amp;D（研究開発）費用は、今年上半期において売上高の3倍以上となる規模だったエディス・テリー氏の執筆

WeRide社がナスダック上昇申請　Didiに続く規模

Hesai Group - American Depositary Share, each ADS represents one Class B ordinary share

Hesai Group

Valvoline Receives Second Request From Federal Trade Commission For Additional Information About The Proposed Acquisition Of Breeze Autocare

Contracts

Trading Ideas

BON Wins $12M 24-Month Supply Agreement To Co-Develop Apple Polyphenol-Infused Health Solutions

Nutriband Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRB#NASDAQ">NTRB</a>)(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NTRBW#NASDAQ">NTRBW</a>), a company engaged in the development of prescription transdermal pharmaceutical products, today announced that it has received notification that its patent has been granted in Macao for its patent entitled, "Abuse and Misuse Deterrent Transdermal Systems," which protects its AVERSA&#x2122; abuse deterrent transdermal technology.
The Macao Intellectual Property Office granted patent J/9010 on February 11, 2025 as recorded in Macao Official Bulletin No. 10 on March 5, 2025. Macao is a Special Administrative Region (SAR) of the People's Republic of China that has its own patent system and patent laws which are separate and distinct from those of mainland China.
The AVERSA&#x2122; abuse deterrent technology is now covered by a broad international intellectual property portfolio with patents issued in 46 countries including the United States, Europe, Japan, Korea, Russia, China, Canada, Mexico, and Australia as well as two regions of China: Hong Kong and Macao.
Nutriband's AVERSA&#x2122; abuse-deterrent technology incorporates aversive agents into transdermal patches to prevent the abuse, diversion, misuse, and accidental exposure of drugs with abuse potential including opioids and stimulants. The AVERSA&#x2122; abuse-deterrent technology has the potential to improve the safety profile of transdermal drugs susceptible to abuse while making sure that these drugs remain accessible to those patients who really need them.
Nutriband is currently working with its partner Kindeva Drug Delivery, a leading global contract development and manufacturing organization focused on drug-device combination products, to develop its lead product, AVERSA&#x2122; Fentanyl, which incorporates Nutriband's AVERSA&#x2122; abuse-deterrent transdermal technology into Kindeva's FDA-approved transdermal fentanyl patch system.
AVERSA Fentanyl has the potential to be the world's first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches. AVERSA Fentanyl has the potential to reach peak annual US sales of $80 million to $200 million.

Government

Regulations

NTRB

NTRBW

Nutriband Secures Macao Patent for AVERSA, Expanding Global Protection for Abuse-Deterrent Opioid Patch, Eyes Up to $200M in Peak US Sales

Mizuho analyst David Belinger initiates coverage on Walmart (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMT#NYSE">WMT</a>) with a Outperform rating and announces Price Target of $105.

Price Target

Initiation

Analyst Ratings

Mizuho Initiates Coverage On Walmart with Outperform Rating, Announces Price Target of $105

ITGR

Integer Holdings Issues Statement On Tariffs, Says 'We continue to estimate an impact of $1 to $5 million on full year adjusted operating income, consistent with previous communications.'

Mizuho analyst David Belinger initiates coverage on Costco Wholesale (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COST#NASDAQ">COST</a>) with a Neutral rating and announces Price Target of $975.

COST

Mizuho Initiates Coverage On Costco Wholesale with Neutral Rating, Announces Price Target of $975

VERV

Verve Therapeutics Receives FDA Fast Track Designation For Its VERVE-102 In Vivo Base Editing Medicine Targeting PCSK9

Biotech

CATX

Perspective Therapeutics Doses First Patient With [212Pb]VMT01 Monotherapy At 1.5 mCi In Phase 1/2a Study Of MC1R-Positive Metastatic Melanoma

Mizuho analyst David Belinger initiates coverage on Target (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TGT#NYSE">TGT</a>) with a Neutral rating and announces Price Target of $92.

Mizuho Initiates Coverage On Target with Neutral Rating, Announces Price Target of $92

WIIM

JPMorgan Chase shares are trading higher after the company reported better-than-expected Q1 EPS and revenues.

Morgan Stanley analyst Kristine Liwag downgrades Joby Aviation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JOBY#NYSE">JOBY</a>) from Overweight to Equal-Weight and lowers the price target from $10 to $7.

Downgrades

JOBY

Morgan Stanley Downgrades Joby Aviation to Equal-Weight, Lowers Price Target to $7

HC Wainwright &amp; Co. analyst Ed Arce reiterates Unicycive Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/UNCY#NASDAQ">UNCY</a>) with a Buy and maintains $7.5 price target.

Reiteration

UNCY

HC Wainwright & Co. Reiterates Buy on Unicycive Therapeutics, Maintains $7.5 Price Target

Earnings

JPMorgan Chase CEO Jamie Dimon: "The economy is facing considerable turbulence (including geopolitics), with the potential positives of tax reform and deregulation and the potential negatives of tariffs and "trade wars," ongoing sticky inflation, high fiscal deficits and still rather high asset prices and volatility."

Fastenal (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FAST#NASDAQ">FAST</a>) reported quarterly earnings of $0.52 per share which met the analyst consensus estimate. This is unchanged from the same period last year. The company reported quarterly sales of $1.96 billion which beat the analyst consensus estimate of $1.95 billion by 0.45 percent. This is a 3.38 percent increase over sales of $1.90 billion the same period last year.

Earnings Beats

FAST

Fastenal Q1 2025 GAAP EPS $0.52, Inline, Sales $1.96B Beat $1.95B Estimate

Keefe, Bruyette &amp; Woods analyst Brady Gailey maintains Bank7 (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BSVN#NASDAQ">BSVN</a>) with a Outperform and lowers the price target from $50 to $47.

BSVN

Keefe, Bruyette & Woods Maintains Outperform on Bank7, Lowers Price Target to $47

HC Wainwright &amp; Co. analyst Vernon Bernardino reiterates Candel Therapeutics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CADL#NASDAQ">CADL</a>) with a Buy and maintains $19 price target.

CADL

HC Wainwright & Co. Reiterates Buy on Candel Therapeutics, Maintains $19 Price Target

JPMorgan Chase (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/JPM#NYSE">JPM</a>) reported quarterly earnings of $5.07 per share which beat the analyst consensus estimate of $4.62 by 9.74 percent. This is a 14.19 percent increase over earnings of $4.44 per share from the same period last year. The company reported quarterly sales of $46.014 billion which beat the analyst consensus estimate of $44.111 billion by 4.31 percent. This is a 8.15 percent increase over sales of $42.548 billion the same period last year.

JPMorgan Chase Q1 2025 GAAP EPS $5.07 Beats $4.62 Estimate, Sales $46.014B Beat $44.111B Estimate

Wells Fargo Q1 net Interest Income Decreased 6%, Driven By The Impact Of Lower Interest Rates On Floating Rate Assets, Deposit Mix And Pricing Changes, Lower Loan Balances, And One Fewer Day In The Quarter, Partially Offset By Lower Market Funding

Needham analyst Mike Matson reiterates Lucid Diagnostics (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LUCD#NASDAQ">LUCD</a>) with a Buy and maintains $3 price target.

LUCD

Needham Reiterates Buy on Lucid Diagnostics, Maintains $3 Price Target

Goldman Sachs analyst Noah Poponak downgrades Booz Allen Hamilton (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/BAH#NYSE">BAH</a>) from Buy to Neutral and lowers the price target from $150 to $109.

Goldman Sachs Downgrades Booz Allen Hamilton to Neutral, Lowers Price Target to $109

Press Releases

HSAI Investor News: Rosen Law Firm Encourages Hesai Group Investors to Inquire About Securities Class Action Investigation - HSAI

Legal

Hesai Group Announcement: If You Have Suffered Losses in Hesai Group (NASDAQ: HSAI), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

HSAI Announcement: Rosen Law Firm Encourages Hesai Group Investors to Inquire About Securities Class Action Investigation - HSAI

Hesai Selected as Exclusive Lidar Provider for Chery's iCAR Targeting the Mass Market

Hesai Group (NASDAQ: HSAI) Securities Fraud Investigation; Investors Urged to Contact Award-Winning Firm, Gibbs Mura

Hesai Lidar Exclusively Powers Baidu Apollo Go's Deployment of Over 1,000 L4 Autonomous Vehicles in Dubai

Hesai Group Files Its Annual Report on Form 20-F

Hesai Lidar Powers WeRide-Uber Autonomous Fleet in Dubai, Backing City's Self-Driving Vision

Rosen Law Firm Encourages Hesai Group Investors to Inquire About Securities Class Action Investigation - HSAI

UBER

Adient

Autoliv

American Axle & Manufacturing Holdings, Inc. Common Stock

American Axle & Mfg Hldgs

BorgWarner

Cooper-Standard Holdings Inc. Common Stock

Cooper-Standard Holdings

Dana

Dorman Products

ECARX Holdings Inc. - Class A Ordinary shares

ECARX Holdings

Fox Factory Holding

Gentex

Garrett Motion

Holley

Luminar Technologies, Inc. - Class A Common Stock

Luminar Technologies

LCI Industries

Lear

Mobileye Global Inc. - Class A Common Stock

Mobileye Global

Modine Manufacturing Company Common Stock

Modine Manufacturing

Patrick Industries

Phinia

QuantumScape Corporation Class A Common Stock

QuantumScape

Standard Motor Products, Inc. Common Stock

Standard Motor Products

Gentherm

Visteon

WeRide

XPEL

Citigroup

Screenshot 2024-11-26 at 9.11.30 PM

Emerging Markets

Movers & Shakers

GWLLF

Hesai Stands Out In LiDAR Market, With Growth In Third Quarter

Benzinga Graphic

Tech

Hesai LiDAR: The Indispensable Guardian Against The Unpredictability Of The Road

Comments

Hesai Gr

ニュース

パートナーシップ

ベンジンガ・グローバル